Back to top
more

ChromaDex (CDXC)

(Delayed Data from NSDQ)

$6.77 USD

6.77
991,249

-0.22 (-3.15%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $6.75 -0.02 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ChromaDex (CDXC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 3.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 15.38% and 2.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will ChromaDex (CDXC) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -9.78%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: ChromaDex (CDXC) Q3 Earnings Expected to Decline

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 20th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    What Falling Estimates & Price Mean for ChromaDex (CDXC)

    by Zacks Equity Research

    ChromaDex (CDXC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

      ChromaDex (CDXC): Moving Average Crossover Alert

      by Zacks Equity Research

      ChromaDex Corporation (CDXC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

        LabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO

        by Zacks Equity Research

        In line with its inorganic growth strategy, LabCorp's (LH) latest Chiltern buyout is aimed at promoting the CRO business.

          LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval

          by Zacks Equity Research

          The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.